Analysis and enlightenment of drug-related administrative penalty cases in medical institutions from 2020 to 2022

WANG Huiling; YUE Zhongsheng; QIAN Yating; CAO Linlin; XIAO Haoxiang; LIU Wei

doi:10.6039/j.issn.1001-0408.2023.21.02

您当前的位置：

首页 >

文章列表页 >

Analysis and enlightenment of drug-related administrative penalty cases in medical institutions from 2020 to 2022

更新时间：2023-11-10

- Analysis and enlightenment of drug-related administrative penalty cases in medical institutions from 2020 to 2022
- ZHONGGUO YAOFANG Vol. 34, Issue 21, Pages: 2578-2582(2023)
- 作者机构：
  
  1.郑州铁路职业技术学院药学院，郑州　450002
  2.郑州大学药学院，郑州　450001
  3.河南省药品审评查验中心，郑州　450008
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.21.02
  CLC： R95
- Published：15 November 2023，
  
  Received：06 May 2023，
  
  Revised：26 August 2023，
扫描看全文
王慧玲,岳中胜,钱雅婷等.2020－2022年医疗机构药品行政处罚案件分析及启示 ^Δ[J].中国药房,2023,34(21):2578-2582.

WANG Huiling,YUE Zhongsheng,QIAN Yating,et al.Analysis and enlightenment of drug-related administrative penalty cases in medical institutions from 2020 to 2022[J].ZHONGGUO YAOFANG,2023,34(21):2578-2582.
王慧玲,岳中胜,钱雅婷等.2020－2022年医疗机构药品行政处罚案件分析及启示 ^Δ[J].中国药房,2023,34(21):2578-2582. DOI： 10.6039/j.issn.1001-0408.2023.21.02.

WANG Huiling,YUE Zhongsheng,QIAN Yating,et al.Analysis and enlightenment of drug-related administrative penalty cases in medical institutions from 2020 to 2022[J].ZHONGGUO YAOFANG,2023,34(21):2578-2582. DOI： 10.6039/j.issn.1001-0408.2023.21.02.

摘要

目的

分析2020－2022年以医疗机构为当事人的药品行政处罚案件的规律和特点，以更好地提高医疗机构药品管理水平。

方法

采用回顾性统计分析法对以医疗机构为当事人的药品行政处罚决定书进行汇总，并将其与2019年版《药品管理法》条款进行匹配并统计分析。

结果

本研究纳入医疗机构为当事人的完整行政处罚决定书144份。按案由分析，劣药案件行政处罚126起，占87.50%，其中过效期药品占劣药案件比例超过50.00%；从无药品经营资格的企业或个人购进药品案件15起，占10.42%。按案件处罚金额的幅度分析，从轻处罚案件34起，占23.61%；减轻处罚案件81起，占56.25%。

结论

因药品管理违法受到行政处罚的医疗机构是极少数，但医疗机构仍应强化守法意识，认识药品管理的“红线”及容易出现的违法行为，以更好地加强药品质量管理。

Abstract

OBJECTIVE

To analyze the patterns and characteristics of drug-related administrative penalty cases with medical institutions as parties from 2020 to 2022 in order to further improve drug management in medical institutions.

METHODS

A retrospective statistical analysis was used to summarize the drug-related administrative penalty decisions with medical institutions as parties， and to match them with the provisions of the

Drug Administration Law

（2019 version） for statistical analysis.

RESULTS

There were 144 complete administrative penalty decisions with medical institutions as parties. Analyzed by cause， 126 cases of administrative punishment for inferior drugs accounted for 87.50%， of which expired drugs accounted for more than 50.00% of the inferior drug cases； 15 cases （10.42%） were for purchasing drugs from enterprises or individuals not qualified to operate drugs. Analyzed by the range of punishment amount of the cases， 34 cases （23.61%） resulted in lighter penalties， while 81 cases （56.25%） resulted in reduced penalties.

CONCLUSIONS

There are extremely few medical institutions that have received administrative penalties for drug management violations. Medical institutions should strengthen the awareness of law-abiding， and know the red line of drug management and the illegal behavior that is easy to occur， so as to better strengthen drug quality management.

关键词

行政处罚药品医疗机构劣药

Keywords

drugmedical institutionsinferior drugs

references

赵艳华. 166起药品行政处罚案件发生特点[J]. 首都医药，2010，17（5）：60-61.

ZHAO Y H. Characteristics of 166 cases of drug admini- strative punishment[J]. Cap Med，2010，17（5）：60-61.

许安标. 《药品管理法》修改的精神要义、创新与发展[J]. 行政法学研究，2020（1）：3-16.

XU A B. On the essence，innovation and development of revised Drug Administration Law[J]. Adm Law Rev，2020（1）：3-16.

苟军仓. 修法强化医疗机构药房监管[N]. 中国医药报，2015-03-30（003）.

GOU J C.Amendments to the law to strengthen the regulation of pharmacies in medical institutions[N]. China Pharmaceutical News，2015-03-30（003）.

张亮，周秋云，侯文洁，等. 医疗机构视角解读新《药品管理法》中使用假劣药的责任[J]. 中国医院药学杂志，2020，40（15）：1679-1683.

ZHANG L，ZHOU Q Y，HOU W J，et al. The responsibi- lity of using counterfeit and inferior drugs in the new Drug Administration Law from the perspective of medical institutions[J]. Chin J Hosp Pharm，2020，40（15）：1679-1683.

邓刚宏，宋叶. 药品行政执法适用免责条款的要件构建[J]. 中国食品药品监管，2021（10）：68-76.

DENG G H，SONG Y. Construction of essential elements for the application of exemption clauses in drug admini- strative enforcement[J]. China Food Drug Adm Mag，2021（10）：68-76.

胡财源. 完善药品监管领域行政处罚裁量制度的探究：基于相关省级药监部门处罚裁量制度的分析[J]. 中国司法，2021（9）：64-68.

HU C Y. Research on perfecting the discretion system of administrative punishment in drug supervision：based on the analysis of the discretion system of relevant provincial drug supervision departments[J]. Justice China，2021（9）：64-68.

谭云. 药品经营使用环节减免违法责任处罚适用情形[J]. 上海医药，2022，43（9）：47-49，57.

TAN Y. Circumstances of application of the reduction or exemption of penalties for illegal liability in the process of drug distribution and usage[J]. Shanghai Med Pharm J，2022，43（9）：47-49，57.

张旭升. “无过错不罚”在药品经营企业的适用及其优化营商环境的意义[J]. 中国食品工业，2022（10）：52-54.

ZHANG X S. The application of “no fault and no punishment” in pharmaceutical trading enterprises and the significance of optimizing business environment[J]. China Food Ind，2022（10）：52-54.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Study on Main Changes of Counterfeit and Inferior Drugs ’Relevant Provisions in the Newly Revised Drug Administration Law and Their Impact on Law Enforcement

Related Author

LIANG Yun

SHAO Rong

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰